Glaxo Pazopanib as Effective as Pfizer Drug in Renal Cancer
This article is for subscribers only.
GlaxoSmithKline Plc’s pazopanib pill for renal cell carcinoma showed similar efficacy to Pfizer Inc.’s sunitinib with fewer side effects in a late-stage study.
For both drugs, on average, patients survived slightly more than 10 months without the disease progressing, according to a study of 1,100 patients. The study, dubbed COMPARZ and funded by London-based drugmaker Glaxo, was released today at the European Society for Medical Oncology meeting in Vienna.